Paarth Shah, MD
Neurology · Gilbert, AZNPI 1356695894
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $202,805 of the $283,345 with a category attached, or 71.6%. 60 manufacturers reported payments, led by Acorda Therapeutics, Inc at 30.8% of the total. Among neurology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,997 payments — averaging $141.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acorda Therapeutics, Inc$87K
- MDD US Operations, LLC$59K
- AbbVie$55K
- Neurocrine Biosciences, Inc.$33K
- Amneal Pharmaceuticals LLC$10K
- Medtronic$10K
- plus $28K from 54 others
Across 3 payments — averaging $5184.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$16K
What the payments were for
- Consulting fees$20,6487%
- Speaking & faculty fees$202,80572%
- Travel & lodging$17,6776%
- Food & beverage$40,92314%
- Education$1,2920%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INBRIJA$84,702
- Duopa$48,717
- INGREZZA$30,965
- APOKYN$28,880
- CREXONT$8,670
- Qutenza$4,600
- REXULTI$4,084
- PERCEPT PC BRAINSENSE$2,161
- LATUDA$2,075
- UPLIZNA$745
- RYTARY$700
- SenSight$528
- Infinity DBS Pulse Generators$515
- INFINITY$469
- ACTIVA$427
- NUEDEXTA$345
- ULTOMIRIS$244
- SPECTRA WAVEWRITER$178
- Prodigy Family of SCS IPGs$142
- Proclaim Family of SCS IPGs$139
How this compares
$283,345 in reported general payments places this provider in the 95th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 34 | $279,830 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 32 | $251,963 |
| AustedoDeutetrabenazine | 23 | $250,263 |
| NuplazidPimavanserin Tartrate | 37 | $180,765 |
| RytaryCarbidopa/Levodopa | 59 | $58,937 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 804 | $30,747 |
| NeuproRotigotine | 25 | $27,844 |
| BotoxOnabotulinumtoxina | 15 | $21,024 |
| RexultiBrexpiprazole | 12 | $18,357 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 217 | $17,824 |
| EliquisApixaban | 13 | $13,084 |
| Ropinirole ErRopinirole Hcl | 96 | $12,487 |
| Pramipexole ErPramipexole Di-Hcl | 40 | $11,822 |
| Rasagiline Mesylate | 48 | $9,523 |
| Xtampza ErOxycodone Myristate | 13 | $8,863 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $32,565 | $279,83034 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $456 | $250,26323 claims |
| Acadia Pharmaceuticals IncNuplazid | $565 | $180,76537 claims |
| Amneal Pharmaceuticals LLCRytary | $10,294 | $58,93759 claims |
| UCB, Inc.Neupro | $1,047 | $27,84425 claims |
| AbbVieBotox | $55,449 | $21,02415 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $4,309 | $18,35712 claims |
| PfizerEliquis | $337 | $13,08413 claims |
| Upsher-smith Laboratories LLCTopiramate | $462 | $31019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 388 neurology providers in Arizona.
Other neurology in Gilbert
- Jonathan HodgsonGilbert$408K
- William GraingerGilbert$211K
- Kan YuGilbert$35K
- Barry HendinPhoenix$2.3M
- Maria OspinaPhoenix$2.1M
- Suraj MuleyPhoenix$1.7M
- Nida LaurinScottsdale$969K
- Eric ErossPhoenix$778K
- Steve ChungPhoenix$685K
- Marwan SabbaghPhoenix$603K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.